{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(10)"],"submitter":["O'Sullivan DE"],"pubmed_abstract":["Real-world evidence surrounding <i>EGFR</i> positive NSCLC patients in Canada is limited. Administrative databases in Alberta, Canada were used to evaluate <i>EGFR</i> testing and mutation prevalence in de novo metastatic NSCLC, as well as the characteristics, treatment patterns, and outcomes of individuals with Exon 19, L858R and Exon20ins mutations. Between 2013-2019, 2974 individuals underwent <i>EGFR</i> testing, of which 451 (15.2%) were <i>EGFR</i> positive. Among <i>EGFR</i> positive individuals, 221 (49.0%) had an Exon 19 mutation, 159 (35.3%) had an L858R mutation, and 18 (4%) had an Exon20ins mutation. The proportion of individuals who initiated 1L systemic therapy was 89.1% for Exon19, 85.5% for L858R, and 72.2% for Exon20ins carriers. The primary front-line systemic therapy was"],"journal":["Current oncology (Toronto, Ont.)"],"pagination":["7198-7208"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9600059"],"repository":["biostudies-literature"],"pubmed_title":["Prevalence, Treatment Patterns, and Outcomes of Individuals with <i>EGFR</i> Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion <i>EGFR</i> Mutation Carriers."],"pmcid":["PMC9600059"],"pubmed_authors":["Gogna P","Rose JB","Jarada TN","Abbie E","Ewara EM","Hu LXY","Eaton K","Brenner DR","Cheung WY","O'Sullivan DE","Elia-Pacitti J","Pabani A","Yusuf A","Boyne DJ"],"additional_accession":[]},"is_claimable":false,"name":"Prevalence, Treatment Patterns, and Outcomes of Individuals with <i>EGFR</i> Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion <i>EGFR</i> Mutation Carriers.","description":"Real-world evidence surrounding <i>EGFR</i> positive NSCLC patients in Canada is limited. Administrative databases in Alberta, Canada were used to evaluate <i>EGFR</i> testing and mutation prevalence in de novo metastatic NSCLC, as well as the characteristics, treatment patterns, and outcomes of individuals with Exon 19, L858R and Exon20ins mutations. Between 2013-2019, 2974 individuals underwent <i>EGFR</i> testing, of which 451 (15.2%) were <i>EGFR</i> positive. Among <i>EGFR</i> positive individuals, 221 (49.0%) had an Exon 19 mutation, 159 (35.3%) had an L858R mutation, and 18 (4%) had an Exon20ins mutation. The proportion of individuals who initiated 1L systemic therapy was 89.1% for Exon19, 85.5% for L858R, and 72.2% for Exon20ins carriers. The primary front-line systemic therapy was","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-22T05:36:39.012Z","creation":"2025-04-05T21:25:17.567Z"},"accession":"S-EPMC9600059","cross_references":{"pubmed":["36290844"],"doi":["10.3390/curroncol29100567"]}}